AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy

April 29, 2026 06:50 AM EDT R&DPharma As­traZeneca cuts a cou­ple of late-stage life-cy­cle tri­als af­ter dis­ap­point­ing ef­fi­ca­cy Elizabeth Cairns Senior biopharma journalist As­traZeneca said it had stopped sev­er­al mid- and late-stage tri­als of some of its pipeline pro­grams in the past few months, po­ten­tial­ly lim­it­ing some of … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER